Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ABL Bio Corp.

www.ablbio.com

Latest From ABL Bio Corp.

Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun

With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.

Deals Asia Pacific

Asia Deal Watch: Daiichi Sankyo Licenses Glycotope's Gatipotuzumab ADC

Daiichi Sankyo gains worldwide rights to an antibody-drug conjugate version of Glycotope’s gatipotuzumab for various cancers. Also, Tasly buys China rights to Mesoblast's CV candidates and India's Cipla grows in Africa.

Asia Pacific Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • ABL Bio Corp.
  • Senior Management
  • Sang Hoon Lee, PhD, CEO
    Jaecheon Jerry Lee, VP, CFO
    Weon-Kyoo You, PhD, VP, Head, R&D
  • Contact Info
  • ABL Bio Corp.
    Phone: 10 9191 5219
    2F, 16 Daewangpangyo-Ro 712 Beon-Gil
    Bundang-Gu
    Seongnam-Si, 13488
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register